e-learning
resources
Barcelona 2013
Sunday, 08.09.2013
Biomarkers in asthma and COPD
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Methylated arginine derivatives can differ stable and unstable patients with COPD
T. Molnar, B. Süto, B. Biri, L. Nagy, S. Keki, I. Ruzsics (Pécs, Debrecen, Hungary)
Source:
Annual Congress 2013 –Biomarkers in asthma and COPD
Session:
Biomarkers in asthma and COPD
Session type:
Oral Presentation
Number:
394
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
T. Molnar, B. Süto, B. Biri, L. Nagy, S. Keki, I. Ruzsics (Pécs, Debrecen, Hungary). Methylated arginine derivatives can differ stable and unstable patients with COPD. Eur Respir J 2013; 42: Suppl. 57, 394
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Respiratory sequelae of preterm birth across the life span
Related content which might interest you:
What is the best biomarker of COPD stability?
Source: International Congress 2015 – COPD: chronic disease and comorbidities
Year: 2015
Role of inflammatory biomarkers in COPD
Source: International Congress 2016 – Systemic biomarkers
Year: 2016
Midrange-proadrenomedullin in stable state predicts severe exacerbation of COPD
Source: International Congress 2016 – Exploring mechanisms in health and disease
Year: 2016
Are there any differences between Tunisian and European COPD phenotypes?
Source: International Congress 2016 – Best abstracts in COPD management
Year: 2016
Clinical and inflammatory characteristics of 'unreported' COPD exacerbations
Source: Annual Congress 2013 –COPD mechanisms
Year: 2013
BNP level in patients with COPD exacerbations
Source: Annual Congress 2013 –Predictors and triggers of asthma and COPD exacerbations
Year: 2013
COPD: Influence of patients’ nutritive status on the exacerbations rate
Source: International Congress 2016 – COPD diagnosis and management
Year: 2016
CAT in COPD phenotypes (POPE study)
Source: International Congress 2016 – Phenotyping and monitoring airway diseases
Year: 2016
COPD on anti-GERD therapy remains at higher risk for severe exacerbation
Source: International Congress 2014 – COPD exacerbations
Year: 2014
Outcomes in patients with COPD during a 3 year follow-up
Source: International Congress 2015 – Clinical assessment and monitoring of asthma and COPD
Year: 2015
Heterogeneity inside group D COPD patients: About 827 cases
Source: International Congress 2016 – Biomarkers and phenotypes of COPD
Year: 2016
Symptom profile of exacerbations in earlier and later COPD
Source: Annual Congress 2013 –Asthma and COPD: diseases with different phenotypes
Year: 2013
Evaluation of the GOLD 2011 severity criteria across the COPD spectrum
Source: Annual Congress 2013 –Predictors and triggers of asthma and COPD exacerbations
Year: 2013
The serum level of surfactantproteind in patients with chronic obstructive pulmonary disease, depending on the nutrtional status
Source: International Congress 2015 – Notable abstracts in exacerbations, mechanisms and biomarkers in COPD
Year: 2015
Eosinophilia as marker of outcome in hospitalised patients with AECOPD
Source: Annual Congress 2013 –COPD and infections
Year: 2013
GOLD and phenotypes: The new Czech COPD guidelines
Source: International Congress 2015 – Novel strategies for the management of asthma, COPD and airway infections
Year: 2015
Characterization of readmissions in patients hospitalized with COPD exacerbation
Source: International Congress 2016 – Novel avenues in the treatment of COPD II
Year: 2016
Gender differences in hospitalized patients with acute exacerbation of COPD
Source: Annual Congress 2013 –COPD biomarkers
Year: 2013
The relation of comorbidities with the exacerbation severity in patients with COPD
Source: Annual Congress 2013 –COPD mechanisms
Year: 2013
The prognostic value of cardiac and inflammatory biomarkers in acute exacerbations of COPD
Source: International Congress 2016 – Biomarkers and phenotypes of COPD
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept